Table 1.
Demographics of Cases
| Variable | Frequency |
|---|---|
| Sex, male | 6 (86) |
| Age, years | 44.8 (31.8–64.2) |
| Ethnicity | |
| White/Non-Hispanic White | 7 (100) |
| Body mass index, kg/m2 | 30 (28–31) |
| Comorbidities | |
| Obesity | 4 (57) |
| Obstructive sleep apnea | 4 (57) |
| Tobacco use | 3 (42) |
| Hypertension | 5 (72) |
| Dyslipidemia | 3 (42) |
| Prior history of myocarditis | 1 (14) |
| Prior history of pericarditis | 1 (14) |
| Previous COVID-19 infection | 1 (14) |
| Type of COVID-19 mRNA vaccine | |
| mRNA-1273 (Moderna) | 4 (57) |
| BNT162b2 (Pfizer-BioNTech) | 3 (42) |
| Time interval between first vaccine and onset of symptoms (range), days | 31 (24–42) |
| Time interval between second vaccine and onset of symptoms (range), days | 3 (3–15) |
| Hospitalization | 6 (86) |
| Duration (range), days | 2 (2–4) |
| Survival to hospital discharge | 7 (100) |
n is the number of patients; % is the percentage of the total number of patients (N = 7 ). Values are n (%) or median (interquartile range) unless otherwise indicated.
Abbreviation: COVID-19, coronavirus disease 2019.